Alpha 2.0
Login Register
» Authors » Concetta Crivera

Concetta Crivera

Explore the profile of Concetta Crivera including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 77
Citations 686
Followers 0
Related Specialties
Pharmacology
General Medicine
Cardiology & Vascular Diseases
Top 10 Co-Authors
Patrick Lefebvre
Francois Laliberte
Craig I Coleman
W Frank Peacock
Jeff Schein
Gregory J Fermann
Jeff R Schein
Veronica Ashton
Erin R Weeda
Winnie W Nelson
Published In
J Med Econ
Curr Med Res Opin
Clin Ther
Am J Hematol
Oncol Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Literature review of occurrence, effectiveness, safety, and hospitalization burden of blood transfusion in the management of warm autoimmune hemolytic anemia
Barros M, Leon A, Crivera C, Cusson E, Kodjamanova P, Bagnall R, et al.
Hematology . 2025 Mar; 30(1):2472489. PMID: 40073280
Introduction: Cases of warm autoimmune hemolytic anemia (wAIHA) often present with life-threatening levels of hemoglobin requiring red blood cell (RBC) transfusion support. Aim: This literature review assessed the occurrence, safety,...
2.
Overall Survival and Treatment Patterns Among Patients With Warm Autoimmune Hemolytic Anemia in Sweden: A Nationwide Population-based Study
Cherif H, Cai Q, Crivera C, Leon A, Rahman I, Leval A, et al.
Eur J Haematol . 2024 Oct; 114(1):129-138. PMID: 39382375
Objectives: Warm autoimmune hemolytic anemia (wAIHA) is a rare autoantibody-mediated disorder, and first-line treatment primarily relies on corticosteroids. This study assessed overall survival (OS) and treatment patterns of wAIHA in...
3.
Healthcare resource utilization of patients with warm autoimmune hemolytic anemia initiating first line therapy of oral corticosteroids with or without rituximab
Murakhovskaya I, Crivera C, Leon A, Alemao E, Anupindi V, DeKoven M, et al.
Ann Hematol . 2024 Jan; 103(4):1139-1147. PMID: 38296903
This retrospective cohort study described real-world treatment patterns and healthcare resource utilization (HCRU) of patients with warm autoimmune hemolytic anemia (wAIHA) initiating treatment with first-line (1L) oral corticosteroids (OCS) + ...
4.
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma
Jagannath S, Joseph N, Crivera C, Kharat A, Jackson C, Valluri S, et al.
Oncol Ther . 2023 Apr; 11(2):263-275. PMID: 37014590
Introduction: Ciltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen-directed, genetically modified autologous chimeric antigen receptor T-cell (CAR-T) immunotherapy. It is indicated for treatment for adult patients with relapsed or refractory...
5.
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
Martin T, Krishnan A, Yong K, Weisel K, Mehra M, Nair S, et al.
EJHaem . 2022 Jul; 3(1):97-108. PMID: 35846215
Introduction: Ciltacabtagene autoleucel (cilta-cel) is a novel chimeric antigen receptor T-cell therapy that is being evaluated in the CARTITUDE-1 trial (NCT03548207) in patients with relapsed or refractory multiple myeloma (RRMM)...
6.
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma
Hoda D, Richards R, Faber E, Deol A, Hunter B, Weber E, et al.
Future Oncol . 2022 May; 18(19):2415-2431. PMID: 35583358
Chimeric antigen receptor T-cell (CAR-T) therapy represents a new frontier in multiple myeloma. It is important to understand critical success factors (CSFs) that may optimize its use in this therapeutic...
7.
Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States
Jagannath S, Joseph N, He J, Crivera C, Fu A, Garrett A, et al.
Oncol Ther . 2022 May; 10(2):411-420. PMID: 35579821
Introduction: The treatment of multiple myeloma (MM) remains a challenge as patients eventually progress through several lines of therapy (LOTs), requiring use of multiple MM drug classes. In this retrospective...
8.
Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US
Jagannath S, Joseph N, He J, Crivera C, Fu A, Garret A, et al.
Oncol Ther . 2021 Oct; 9(2):659-669. PMID: 34694578
Introduction: Multiple myeloma (MM) is a malignancy of plasma cells; most MM patients will eventually relapse or become refractory to treatment. Treating MM patients remains a challenge since patients eventually...
9.
Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review
Sussman M, Crivera C, Benner J, Adair N
Adv Ther . 2021 Jul; 38(8):4178-4194. PMID: 34251651
Introduction: Traditional statistical techniques for extrapolating short-term survival data for anticancer therapies assume the same mortality rate for noncured and "cured" patients, which is appropriate for projecting survival of non-curative...
10.
Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations
Shah N, Sussman M, Crivera C, Valluri S, Benner J, Jagannath S
Clin Drug Investig . 2021 Feb; 41(3):201-210. PMID: 33598857
Background And Objective: Registrational trials for ciltacabtagene autoleucel [cilta-cel]) and idecabtagene vicleucel [ide-cel] chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma (MM) patients...